Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Correspondence
Nature Medicine 15, 726 (1 July 2009) | doi:10.1038/nm0709-726
Will integrin inhibitors have proangiogenic effects in the clinic?
&
Abstract
To the Editor: In a comprehensive analysis, Reynolds et al. recently reported that RGD-mimetic agents such as cilengitide may, under certain experimental conditions, promote rather than inhibit angiogenesis. They accordingly express their reservations regarding the clinical exploration of such agents in human patients with cancer.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
